Inflammation Biomarkers Are Associated with the Incidence of Cardiovascular Disease: a Meta-analysis

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2023 Jul 24

PMID 37485268

Authors

Yifei Liu

Suzhen Guan

Haiming Xu

Na Zhang

Min Huang

Zhihong Liu

Affiliations

Soon will be listed here.

Abstract

Background: Inflammation is a risk factor for cardiovascular disease (CVD), and particular inflammatory parameters can be used to predict the incidence of CVD. The aim of this study was to assess the association between fibrinogen (FIB), interleukin-6 (IL-6), C-reactive protein (CRP) and galectin-3 (Gal-3) and the risk of cardiovascular disease using meta-analysis.

Methods: PubMed, Embase, Scopus, and Web of Science databases were searched with the appropriate strategies to identify observational studies relevant to this meta-analysis. A random-effects model was used to combine inflammation factor-associated outcomes and cardiovascular disease outcomes, except in the case of galectin-3, where a fixed-effects model was used because of less heterogeneity. Location, age, type of cardiovascular disease, and sample size factors were used to explore heterogeneity in stratification and metaregression for subgroup analysis. A case-by-case literature exclusion approach was used for sensitivity analysis. The funnel plot and Begg's test were combined to assess publication bias.

Results: Thirty-three papers out of 11,456 were screened for inclusion in the analysis. Four inflammation biomarkers were significantly associated with the development of CVD: FIB (OR: 1.21, 95% CI: 1.15-1.27, < 0.001; HR: 1.04, 95% CI: 1.00-1.07, < 0.05), IL-6 (HR: 1.16, 95% CI: 1.10-1.22, < 0.001), CRP (OR: 1.25, 95% CI: 1.15-1.35, < 0.001; HR: 1.20, 95% CI: 1.14-1.25, < 0.001) and Gal-3 (HR: 1.09, 95% CI: 1.05-1.14, < 0.001). Location factors help explain the source of heterogeneity, and there is publication bias in the Gal-3 related literature.

Conclusion: Taken together, the current research evidence suggests that high levels of fibrinogen, interleukin-6, C-reactive protein and galectin-3 are risk factors for cardiovascular disease and can be used as biomarkers to predict the development of cardiovascular disease to some extent.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO, identifier: CRD42023391844.

Citing Articles

Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk.

Klisic A, Gluscevic S, Karakasis P, Kotur-Stevuljevic J, Ninic A J Med Biochem. 2025; 44(1):85-92.

PMID: 39991168 PMC: 11846640. DOI: 10.5937/jomb0-50471.

Colchicine for the primary prevention of cardiovascular events.

Marti-Carvajal A, Gemmato-Valecillos M, Monge Martin D, De Sanctis J, Marti-Amarista C, Hidalgo R Cochrane Database Syst Rev. 2025; 2:CD015003.

PMID: 39927511 PMC: 11808834. DOI: 10.1002/14651858.CD015003.pub2.

Distinctive blood and salivary proteomics signatures in Qatari individuals at high risk for cardiovascular disease.

Yousif G, Murugesan S, Djekidel M, Terranegra A, Gentilcore G, Grivel J Sci Rep. 2025; 15(1):4056.

PMID: 39901062 PMC: 11790934. DOI: 10.1038/s41598-025-87596-2.

Therapeutic effects of platelet-derived extracellular vesicles on viral myocarditis correlate with biomolecular content.

Beetler D, Giresi P, Di Florio D, Fliess J, McCabe E, Watkins M Front Immunol. 2025; 15():1468969.

PMID: 39835120 PMC: 11743460. DOI: 10.3389/fimmu.2024.1468969.

Association of systemic immune-inflammation index with all-cause and cardiovascular mortality among adults with depression: evidence from NHANES 2005-2018.

Yu X, Zheng H, Liu M, Wu L, Tian S, Wu W BMC Psychiatry. 2025; 25(1):25.

PMID: 39780080 PMC: 11707943. DOI: 10.1186/s12888-024-06463-y.

References

Kaiser H, Wang X, Kvist-Hansen A, Krakauer M, Gortz P, McCauley B . Biomarkers of subclinical atherosclerosis in patients with psoriasis. Sci Rep. 2021; 11(1):21438. PMC: 8564536. DOI: 10.1038/s41598-021-00999-9. View

Ridker P . From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016; 118(1):145-56. PMC: 4793711. DOI: 10.1161/CIRCRESAHA.115.306656. View

Silverman M, Patel B, Blankstein R, Lima J, Blumenthal R, Nasir K . Impact of Race, Ethnicity, and Multimodality Biomarkers on the Incidence of New-Onset Heart Failure With Preserved Ejection Fraction (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2016; 117(9):1474-81. PMC: 4999314. DOI: 10.1016/j.amjcard.2016.02.017. View

Roth G, Mensah G, Johnson C, Addolorato G, Ammirati E, Baddour L . Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25):2982-3021. PMC: 7755038. DOI: 10.1016/j.jacc.2020.11.010. View

Subirana I, Fito M, Diaz O, Vila J, Frances A, Delpon E . Prediction of coronary disease incidence by biomarkers of inflammation, oxidation, and metabolism. Sci Rep. 2018; 8(1):3191. PMC: 5816603. DOI: 10.1038/s41598-018-21482-y. View

Jatho A, Cambia J, Myung S . Consumption of artificially sweetened soft drinks and risk of gastrointestinal cancer: a meta-analysis of observational studies. Public Health Nutr. 2021; 24(18):6122-6136. PMC: 11148581. DOI: 10.1017/S136898002100104X. View

Shaw L, Merz C, Pepine C, Reis S, Bittner V, Kelsey S . Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006; 47(3 Suppl):S4-S20. DOI: 10.1016/j.jacc.2005.01.072. View

Daniels L, Clopton P, Laughlin G, Maisel A, Barrett-Connor E . Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. Am Heart J. 2014; 167(5):674-82.e1. PMC: 4012893. DOI: 10.1016/j.ahj.2013.12.031. View

Kraler S, Wenzl F, Georgiopoulos G, Obeid S, Liberale L, von Eckardstein A . Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes. Eur Heart J. 2022; 43(19):1849-1860. DOI: 10.1093/eurheartj/ehac143. View

10.

Everett B, Ridker P, Cook N, Pradhan A . Usefulness of B-type Natriuretic Peptides to Predict Cardiovascular Events in Women (from the Women's Health Study). Am J Cardiol. 2015; 116(4):532-7. PMC: 4586028. DOI: 10.1016/j.amjcard.2015.05.014. View

11.

Shivappa N, Godos J, Hebert J, Wirth M, Piuri G, Speciani A . Dietary Inflammatory Index and Cardiovascular Risk and Mortality-A Meta-Analysis. Nutrients. 2018; 10(2). PMC: 5852776. DOI: 10.3390/nu10020200. View

12.

. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1151-1210. PMC: 5605883. DOI: 10.1016/S0140-6736(17)32152-9. View

13.

Vasan R, Sullivan L, Roubenoff R, Dinarello C, Harris T, Benjamin E . Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003; 107(11):1486-91. DOI: 10.1161/01.cir.0000057810.48709.f6. View

14.

Gaye B, Tafflet M, Arveiler D, Montaye M, Wagner A, Ruidavets J . Ideal Cardiovascular Health and Incident Cardiovascular Disease: Heterogeneity Across Event Subtypes and Mediating Effect of Blood Biomarkers: The PRIME Study. J Am Heart Assoc. 2017; 6(10). PMC: 5721848. DOI: 10.1161/JAHA.117.006389. View

15.

Kraler S, Wenzl F, Luscher T . Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial. Eur J Clin Invest. 2020; 50(12):e13424. DOI: 10.1111/eci.13424. View

16.

Cesari M, Penninx B, Newman A, Kritchevsky S, Nicklas B, Sutton-Tyrrell K . Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003; 108(19):2317-22. DOI: 10.1161/01.CIR.0000097109.90783.FC. View

17.

de Boer R, Nayor M, deFilippi C, Enserro D, Bhambhani V, Kizer J . Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiol. 2018; 3(3):215-224. PMC: 5862778. DOI: 10.1001/jamacardio.2017.4987. View

18.

Nafari A, Mohammadifard N, Haghighatdoost F, Nasirian S, Najafian J, Sadeghi M . High-sensitivity C-reactive protein and low-density lipoprotein cholesterol association with incident of cardiovascular events: Isfahan cohort study. BMC Cardiovasc Disord. 2022; 22(1):241. PMC: 9131566. DOI: 10.1186/s12872-022-02663-0. View

19.

Cai X, Sun L, Liu X, Zhu H, Zhang Y, Zheng S . Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease. Ther Adv Chronic Dis. 2021; 12:20406223211024361. PMC: 8237225. DOI: 10.1177/20406223211024361. View

20.

Dawood F, Judd S, Howard V, Limdi N, Meschia J, Cushman M . High-Sensitivity C-Reactive Protein and Risk of Stroke in Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol. 2016; 118(12):1826-1830. PMC: 5127742. DOI: 10.1016/j.amjcard.2016.08.069. View